Ozekibart

奥泽奇拜单抗

Report date: 2024/02/05 11:22:49

Base Information

Drug NameOzekibart
Drug Alias NameJCT-205INBRX-109
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Biologics > Protein drugs > Recombinant protein
Mechanisms of ActionTumor necrosis factor receptor superfamily member 10B agonists
TargetsTumor necrosis factor receptor superfamily member 10B
Therapy Area/IndicationsAdenocarcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesInhibrx Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesTranscenta Holding LtdHJB (Hangzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsAdenocarcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A